IP Library Granted Patent US 9,206,484
Granted Patent B2
US 9,206,484 · App. 13/642,428 · Granted Dec 8, 2015

Compositions, methods and kits to detect herpes simplex virus nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,206,484
App. No.
13/642,428
Granted
Dec 8, 2015
Kind
B2
Abstract

The disclosed invention is related to methods, compositions, kits and isolated nucleic acid sequences for targeting Herpes Simplex Virus (HSV) nucleic acid (eg. HSV-1 and/or HSV-2 nucleic acid). Compositions include amplification oligomers, detection probe oligomers and/or target capture oligomers. Kits and methods comprise at least one of these oligomers.

Claims (26)

1. A method for specifically detecting a Herpes Simplex Virus-1 (HSV-1) target nucleic acid in a sample comprising the steps of:

(a) providing a sample suspected of containing at least a HSV-1 target nucleic acid;

(b) contacting said sample with at least two amplification oligomers, wherein a first of said amplification oligomers comprises a target hybridizing sequence 15 to 25 nucleotides in length and configured to target a sequence in a region of the HSV-1 US8.5 ORF corresponding to nucleotides 124 to 156 of SEQ ID NO:1, and wherein a second of said amplification oligomers comprises a target hybridizing sequence comprising SEQ ID NO:10; and

(c) performing a nucleic acid detection reaction with a detection probe configured to detect a sequence in a region corresponding to nucleotides 173 to 196 of SEQ ID NO:1 that detects an amplification product to determine whether a HSV-1 target nucleic acid is present in said sample.

2. The method of claim 1 , wherein said first of said amplification oligomers comprises a target hybridizing sequence wherein said target hybridizing sequence consists of SEQ ID NO:7, or wherein said target hybridizing sequence consists of SEQ ID NO:8.

3. The method of claim 1 , wherein said second of said amplification oligomers further comprises a 5′ promoter sequence.

4. The method of claim P, wherein said detection is real-time detection.

5. The method of claim 1 , wherein said detection probe has a sequence consisting of SEQ ID NO:13, or consisting of SEQ ID NO: 14.

6. The method of claim 1 , further comprising the step of contacting said sample with a target capture oligomer.

7. The method of claim 6 , wherein said target capture oligomer is configured to hybridize to a US8.5 nucleic acid from HSV-1 and HSV-2.

8. The method of claim 6 , wherein said target capture oligomer comprises a target hybridizing sequence consisting of SEQ ID NO:3, or SEQ ID NO:5.

9. The method of claim 1 , wherein said amplification product is produced in an isothermal amplification reaction, a transcription mediated amplification reaction, or a strand displacement amplification reaction.

10. The method of claim 1 , wherein said amplification product is an RNA amplification product.

11. The method of claim 1 wherein the first of said amplification oligomers comprises a target hybridizing sequence consisting of SEQ ID NOS:7, or 8; and wherein the second of said amplification oligomers comprises a target hybridizing sequence consisting of SEQ ID NO:10 joined at its 5′ end to a promoter sequence; and wherein step (c) is performed using a detection probe oligomer the sequence of which consists of SEQ ID NO:13 or SEQ ID NO:14.

12. A composition for use in a Herpes Simplex Virus-1 (HSV-1) target nucleic acid amplification assay comprising at least two amplification oligomers capable of stably hybridizing to a HSV-1 US8.5 target nucleic acid, wherein the at least two amplification oligomers comprise first amplification oligomers and second amplification oligomers, wherein the first amplification oligonucleotides comprise a target binding sequence consisting of SEQ ID NO:7 or 8, and the second amplification oligonucleotides comprise a target binding sequence consisting of SEQ ID NO:10 joined at its 5′ end to a promoter sequence, wherein pairs of the first and second amplification oligonucleotides can hybridize to opposing strands of HSV-1 nucleic acid for transcription mediated amplification of the US8.5 target nucleic acid between hybridized pairs of the first and second amplification oligonucleotides.

13. The composition of claim 12 , wherein the sequence of the second amplification oligomer consists of SEQ ID NO:9.

14. The composition of claim 12 , further comprising a detection probe oligomer, the sequence of which consists of SEQ ID NO:13 or SEQ ID NO:14.

15. The composition of claim 14 , wherein at least one nucleotide in the detection probe oligomer sequence further comprises a modification selected from the group consisting of: 2′ methoxy substitutions and 2′ halide substitutions.

16. The composition of claim 12 , further comprising a target capture oligomer.

17. The composition of claim 16 , wherein said target capture oligomer is configured to hybridize to a US8.5 nucleic acid from HSV-1 and HSV-2.

18. The composition of claim 16 , wherein said target capture oligomer comprises a target binding region consisting of SEQ ID NO:3, or SEQ ID NO:5.

19. A kit comprising the composition of claim 12 , and optionally a set of instructions for using same.

20. The method of claim 1 , wherein the second of said amplification oligomers comprises a-sequence consisting of SEQ ID NO:9.

21. The method of claim 5 , wherein at least one nucleotide in the detection probe oligomer sequence further comprises a modification selected from the group consisting of: 2′ methoxy substitutions and 2′ halide substitutions.

22. The method of claim 21 , wherein the 2′ halide substitution is a 2′-F substitution.

23. The composition of claim 15 , wherein the 2′ halide substitution is a 2′-F substitution.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2016
From: GETMAN, DAMON K.; AIYER, APARNA; CHEN, WENDY
To: GEN-PROBE INCORPORATED
Reel/Frame 038637/0254 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →